Keywords: Roche, Genentech, Avastin, USA, FDA, Europe, EMA, Breast cancer, Somatropin, Growth hormone

US FDA to halt breast cancer use for Roche’s Avastin, but EMA says it’s OK in combo with paclitaxel; no immediate somatropin concerns

Article | 17 December 2010

Print This

The US Food and Drug Administration yesterday said that it is recommending removing the breast cancer indication from the label ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in